Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring the Molecular Mechanism of Secondary Resistance to Imatinib in Gastrointestinal Stromal Tumors Based on KIT Mutation

NCT05895942 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT05895942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05895942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring the Molecular Mechanism of Secondary Resistance to Imatinib in Gastrointestinal Stromal Tumors Based on KIT Mutation
Lead sponsor
Xijing Hospital
Phase
Observational
Overall status
Unknown status
Start date
September 10, 2021
Completion date
September 10, 2025
Enrollment
190 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gist